Cite
MLA Citation
S. Verstovsek et al.. “S195: MOMENTUM: PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) IN SYMPTOMATIC AND ANEMIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR.” HemaSphere, vol. 6, n.d., pp. 96–97. http://access.bl.uk/ark:/81055/vdc_100158013909.0x000007